Barriers and facilitators to implementation of the interoperable Survivorship Passport (SurPass) v2.0 in 6 European countries: a PanCareSurPass online survey study.

Autor: van den Oever SR; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands. s.r.vandenoever-2@prinsesmaximacentrum.nl., de Beijer IAE; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands., Kremer LCM; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.; University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, The Netherlands.; Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Alfes M; CCI Europe, Vienna, Austria., Balaguer J; Hospital Universitario y Politécnico La Fe, Valencia, Spain., Bardi E; St. Anna Children's Hospital, Vienna, Austria.; Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria., Nieto AC; Hospital Universitario y Politécnico La Fe, Valencia, Spain., Cangioli G; HL7 Europe, Brussels, Belgium., Charalambous E; HL7 Europe, Brussels, Belgium., Chronaki C; HL7 Europe, Brussels, Belgium., Costa T; CCI Europe, Vienna, Austria., Degelsegger A; Gesundheit Österreich GMBH, Vienna, Austria., Düster V; St. Anna Children's Cancer Research Institute, Vienna, Austria., Filbert AL; University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany., Grabow D; University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany., Gredinger G; Gesundheit Österreich GMBH, Vienna, Austria., Gsell H; CCI Europe, Vienna, Austria., Haupt R; IRCCS Istituto Giannina Gaslini, Genova, Italy., van Helvoirt M; University Hospitals Leuven, KU, Louvain, Belgium., Ladenstein R; St. Anna Children's Hospital, Vienna, Austria.; St. Anna Children's Cancer Research Institute, Vienna, Austria., Langer T; Universitatsklinikum Schleswig-Holstein, Campus Lubeck, Lubeck, Germany., Laschkolnig A; Gesundheit Österreich GMBH, Vienna, Austria., Muraca M; IRCCS Istituto Giannina Gaslini, Genova, Italy., Rascon J; Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania., Schreier G; AIT Austrian Institute of Technology, Graz, Austria., Tomasikova Z; CCI Europe, Vienna, Austria., Tormo MT; Instituto Investigación Sanitaria La Fe, Valencia, Spain., Trinkunas J; Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania., Trollip J; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands., Trunner K; Gesundheit Österreich GMBH, Vienna, Austria., Uyttebroeck A; Universitatsklinikum Schleswig-Holstein, Campus Lubeck, Lubeck, Germany., van der Pal HJH; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands., Pluijm SMF; Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.
Jazyk: angličtina
Zdroj: Journal of cancer survivorship : research and practice [J Cancer Surviv] 2024 Jun; Vol. 18 (3), pp. 928-940. Date of Electronic Publication: 2023 Feb 20.
DOI: 10.1007/s11764-023-01335-y
Abstrakt: Purpose: Long-term follow-up (LTFU) care for childhood cancer survivors (CCSs) is essential to improve and maintain their quality of life. The Survivorship Passport (SurPass) is a digital tool which can aid in the delivery of adequate LTFU care. During the European PanCareSurPass (PCSP) project, the SurPass v2.0 will be implemented and evaluated at six LTFU care clinics in Austria, Belgium, Germany, Italy, Lithuania and Spain. We aimed to identify barriers and facilitators to the implementation of the SurPass v2.0 with regard to the care process as well as ethical, legal, social and economical aspects.
Methods: An online, semi-structured survey was distributed to 75 stakeholders (LTFU care providers, LTFU care program managers and CCSs) affiliated with one of the six centres. Barriers and facilitators identified in four centres or more were defined as main contextual factors influencing implementation of SurPass v2.0.
Results: Fifty-four barriers and 50 facilitators were identified. Among the main barriers were a lack of time and (financial) resources, gaps in knowledge concerning ethical and legal issues and a potential increase in health-related anxiety in CCSs upon receiving a SurPass. Main facilitators included institutions' access to electronic medical records, as well as previous experience with SurPass or similar tools.
Conclusions: We provided an overview of contextual factors that may influence SurPass implementation. Solutions should be found to overcome barriers and ensure effective implementation of SurPass v2.0 into routine clinical care.
Implications for Cancer Survivors: These findings will be used to inform on an implementation strategy tailored for the six centres.
(© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: